123 completed, 30 recruiting, 30 terminated, 29 active not recruiting. 135 Phase 2, 99 Phase 1, 56 Phase 3, 3 Phase 4, 1 Early Phase 1.
Follow Bendamustine: new trials by email Literature Review of Bendamustine trials Research Report on Bendamustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma Orelabrutinib, obinutuzumab, Lenalidomide - Follicular Lymphoma ( FL) | Phase 3 | Not yet recruiting | Ruijin Hospital | 652 | 2026-07-01 | 2026-07-22 |
| A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) MK-1045, Rituximab, Rituximab biosimilar - Follicular Lymphoma | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 960 | 2026-06-22 | 2026-10-26 |
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
| Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis TRX319, Bendamustine - Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS) | Phase 1 / Phase 2 | Recruiting | Tr1X, Inc. | 39 | 2026-03-01 | 2026-09-21 |
| A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma Rocbrutinib, Bendamustine, Rituximab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 150 | 2025-11-27 | 2025-12-16 |
| A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) DZD8586, Bendamustine, Idelalisib - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 3 | Recruiting | Dizal Pharmaceuticals | 250 | 2025-09-08 | 2026-06-03 |
| Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia Ibrutinib, Bendamustine, Rituximab - Waldenström Macroglobulinemia (WM) | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 21 | 2025-09-01 | 2025-09-11 |
| A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) Golcadomide, Rituximab, Lenalidomide - Follicular Lymphoma | Phase 3 | Recruiting | Celgene | 400 | 2025-07-28 | 2026-05-20 |
| Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study Zanubrutinib, Obinutuzumab, Bendamustine - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | The First Hospital of Jilin University | 30 | 2025-06-15 | 2025-06-04 |
| MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma Bendamustine, Rituximab - Lymphoma, Indolent Non-hodgkin Lymphoma | Phase 2 | Not yet recruiting | Fox Chase Cancer Center | 24 | 2025-06-01 | 2025-01-06 |
| A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors BGB-16673, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | BeOne Medicines | 153 | 2025-05-29 | 2026-08-24 |
| A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype Duvelisib, Gemcitabine, Bendamustine - Lymphoma | Phase 3 | Recruiting | SecuraBio | 124 | 2025-05-19 | 2026-04-06 |
| Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A Obinutuzumab, CHOP, Bendamustine - Follicular Lymphoma Grade 3A | Phase 2 | Not yet recruiting | Sun Yat-sen University | 133 | 2025-05-01 | 2025-05-08 |
| BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma Bendamustine, Rituximab, Cytarabine - Mantle Cell Lymphoma, Lymphoma | Phase 2 | Recruiting | Christine Ryan | 60 | 2025-04-22 | 2026-02-20 |
| Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer Bendamustine, Biopsy, Biospecimen Collection - Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-15 | 2025-04-01 | |
| A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors Tacabrutideg, Bendamustine, Idelalisib - CLL, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | BeOne Medicines | 250 | 2025-04-10 | 2026-09-28 |
| Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma Zuberitamab, Bendamustine - Follicular Lymphoma (FL) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 50 | 2025-02-01 | 2025-01-03 |
| BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma Brentuximab Vedotin (Bv), Sintilimab, Tislelizumab - Hodgkin Lymphoma (Category) | Phase 4 | Not yet recruiting | Xiuhua Sun | 100 | 2024-12-31 | 2025-01-07 |
| Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM Zanubrutinib, Bendamustine, Rituximab - Waldenstrom Macroglobulinemia | Phase 2 | Recruiting | Massachusetts General Hospital | 65 | 2024-12-20 | 2026-09-01 |
| MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 12 | 2024-09-20 | 2026-03-16 |
Showing 20 of 255. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (64) · Lymphoma, Non-Hodgkin (51) · Lymphoma (49) · Lymphoma, Follicular (43) · Lymphoma, Mantle-Cell (36) · Lymphoma, Large B-Cell, Diffuse (27) · Hodgkin Disease (25) · Multiple Myeloma (24) · Recurrence (23) · Lymphoma, B-Cell, Marginal Zone (20) · Lymphoma, B-Cell (15) · Leukemia (14) · Waldenstrom Macroglobulinemia (10) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Neoplasms (8)
Hoffmann-La Roche (15) · M.D. Anderson Cancer Center (11) · German CLL Study Group (9) · Fate Therapeutics (8) · UNC Lineberger Comprehensive Cancer Center (6) · Fred Hutchinson Cancer Center (5) · Genentech, Inc. (5) · Celgene (4) · Cephalon (4) · Fondazione Italiana Linfomi - ETS (4) · Gilead Sciences (4) · Mayo Clinic (4) · Merck Sharp & Dohme LLC (4) · SCRI Development Innovations, LLC (4) · BeOne Medicines (3)
United States (170) · Italy (52) · Germany (48) · France (47) · Spain (43) · United Kingdom (42) · Canada (38) · Australia (36) · Poland (34) · China (32) · Belgium (29) · South Korea (28) · Czechia (23) · Russia (22) · Taiwan (21)
Natalie Grover, MD (4) · Paula Cramer, Dr. med. (4) · Julie Chang, MD (3) · Armando Santoro, MD (2) · Brad S Kahl, M.D. (2) · Christine Ryan, MD (2)
PMID 38620092, PMID 31050355, PMID 32126141, PMID 34086865, PMID 19860608, PMID 21239695, PMID 21816833, PMID 21844497, PMID 22451423, PMID 22869884, PMID 23109692, PMID 23430121, PMID 23433739, PMID 23753028, PMID 23843495, PMID 23955074, PMID 24359243, PMID 24591201, PMID 24925211, PMID 25145344, PMID 25355819, PMID 25769620, PMID 25911554, PMID 26239087, PMID 26331432, PMID 26377597, PMID 26659915, PMID 26729345, PMID 26875824, PMID 26913697, PMID 27222473, PMID 27233802, PMID 27345636, PMID 27382096, PMID 27442600, PMID 27695295, PMID 28011903, PMID 28031173, PMID 28976863, PMID 29038340, PMID 29226797, PMID 29276022, PMID 29296805, PMID 29562156, PMID 29584548, PMID 29703778, PMID 29749403, PMID 29856692, PMID 29908231, PMID 30309758
2015 (8), 2014 (6), 2023 (6), 2016 (5), P30CA012197 (3), 2009 (2), 2017 (2), 2018 (2), 2019 (2), P30CA138292 (2), U10CA180820 (2), 2005 (1), 2008 (1), 2025 (1), K12CA076930 (1)